These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
43. Effects of Resmetirom on Noninvasive Endpoints in a 36-Week Phase 2 Active Treatment Extension Study in Patients With NASH. Harrison SA; Bashir M; Moussa SE; McCarty K; Pablo Frias J; Taub R; Alkhouri N Hepatol Commun; 2021 Apr; 5(4):573-588. PubMed ID: 33860116 [TBL] [Abstract][Full Text] [Related]
44. Liver stiffness measurement by magnetic resonance elastography is not affected by hepatic steatosis. Chen J; Allen AM; Therneau TM; Chen J; Li J; Hoodeshenas S; Chen J; Lu X; Zhu Z; Venkatesh SK; Song B; Ehman RL; Yin M Eur Radiol; 2022 Feb; 32(2):950-958. PubMed ID: 34432123 [TBL] [Abstract][Full Text] [Related]
45. Accuracy of FibroScan Controlled Attenuation Parameter and Liver Stiffness Measurement in Assessing Steatosis and Fibrosis in Patients With Nonalcoholic Fatty Liver Disease. Eddowes PJ; Sasso M; Allison M; Tsochatzis E; Anstee QM; Sheridan D; Guha IN; Cobbold JF; Deeks JJ; Paradis V; Bedossa P; Newsome PN Gastroenterology; 2019 May; 156(6):1717-1730. PubMed ID: 30689971 [TBL] [Abstract][Full Text] [Related]